The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Data were analyzed from two multicenter phase 3 studies of single-agent ibrutinib: RESO-NATE (PCYC-1112) in patients with R/R CLL and RESONATE-2 (PCYC-1115) in patients with treatment-naive (TN) CLL without del(17p).
271 ibrutinib-treated non-del(17p) patients with CLL (136 TN and 135 R/R). Median progression-free survival (PFS) was not reached for subgroups with 0 and 1/2 prior therapies but was 40.6 months for patients with ≥3 therapies (median follow-up: TN, 36 months; R/R, 44 months). Median overall survival (OS) was not reached in any subgroup. Overall response rate (ORR) was 92% in TN and 92% in R/R, with depth of response increasing over time. Adverse events (AEs) and ibrutinib discontinuation due to AEs were similar between patient groups. Most patients (64%) remain on treatment. OS following discontinuation was 9.3 months in R/R patients (median follow-up 18 months, n = 51) and was not reached in TN patients (median follow-up 10 months, n = 30). In this integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR regardless of prior therapies in patients with CLL. The best outcomes following ibrutinib discontinuation were for patients receiving ibrutinib in earlier lines of therapy.
| INTRODUCTION
The B-cell receptor (BCR) signaling pathway has emerged as an important therapeutic target for B-cell malignancies, including chronic lymphocytic leukemia (CLL). 1 Bruton's tyrosine kinase (BTK), a component of signaling via the BCR, plays a role in the survival, proliferation, tissue adhesion, and migration of CLL cells. [1] [2] [3] [4] [5] Ibrutinib, a firstin-class, once-daily oral BTK inhibitor, is indicated by the United
States Food and Drug Administration and the European Medicines
Agency for treating patients with CLL, including del(17p) CLL, and allows for treatment without chemotherapy. Results from the phase 3 RESONATE-2 study (PCYC-1115) of ibrutinib versus chlorambucil in treatment-naive (TN) patients with CLL showed significantly prolonged progression-free survival (PFS) and overall survival (OS) with ibrutinib. 6 In patients with relapsed/refractory (R/R) CLL, the phase 3 RESONATE study (PCYC-1112) of ibrutinib versus ofatumumab showed superior PFS and OS with ibrutinib. 7 Data from RESONATE suggest that outcomes with ibrutinib in the relapsed setting vary by extent of prior therapy; patients treated with ibrutinib after one prior regimen experience significantly longer PFS than patients treated in later lines. 8 As BCR signaling inhibitors are only recently available for CLL, and patients discontinue infrequently, few studies have evaluated patient outcomes following cessation of ibrutinib. Recent institutional analyses that included high-risk, multiply relapsed patients reported poor survival in those who discontinued ibrutinib. 9, 10 We conducted an integrated analysis of two phase 3 studies to evaluate outcomes with ibrutinib in CLL based on the number of prior lines of therapy, including after ibrutinib discontinuation.
| PATIENTS AND METHODS

| Patients, treatment regimen, and clinical end points
Data were analyzed from patients from two multicenter, randomized phase 3 studies of single-agent ibrutinib: RESONATE-2 (NCT01722487)
in TN patients ≥65 years of age 6 and RESONATE (NCT01578707)
in patients with CLL treated with ≥1 prior therapy, as previously described. 6,7 RESONATE-2 excluded patients with del(17p); therefore, this subgroup was also excluded from RESONATE for this analysis to ensure a homogeneous dataset. Patients treated with 1 to 2 prior lines of therapy were combined because the number of patients treated with one prior therapy was small (n = 27).
In both studies, patients on the ibrutinib arm received ibrutinib 420 mg once daily continuously. Patients on the comparator arm received up to 12 cycles of chlorambucil (RESONATE-2)
or 24 weeks of intravenous ofatumumab (RESONATE), and those patients with progression confirmed by an Independent Review Committee were allowed to cross over to ibrutinib. 6, 7 Details regarding drug administration have been previously published. 6, 7 Clinical end points included PFS, OS, overall response rate (ORR), and safety (grading of severity of adverse events [AEs] based on CTCAE 4.0). In addition, OS post-discontinuation of ibrutinib and comparator treatments were assessed. PFS and ORR were based on investigator assessment.
Studies were approved by the institutional review boards at each participating institution and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
RESONATE and RESONATE-2 were registered at www.clinicaltrials.
gov as NCT01578707 and NCT01722487.
| Statistical considerations
Patient subgroups were defined according to the number of lines of therapy received before ibrutinib (0, 1-2, ≥3 prior lines). Descriptive analysis was used to summarize demographics, baseline characteristics, and safety. OS post-discontinuation was measured from the date of ibrutinib discontinuation to the date of last follow-up or death.
Time-to-event end points were estimated using the Kaplan-Meier method.
3 | RESULTS was not significant (P = 0.2387). The 36-month PFS rate for each group was 81%, 74%, and 54%, respectively. In patients with del(11q), median PFS was 38.5 months for patients with ≥3 prior therapies, and was not reached for patients with 0 to 2 prior therapies (data not shown). Median OS was not reached in any subgroup. The difference in OS between 0 versus ≥3 lines of therapy was significant (P = 0.0091); differences in OS between 0 versus 1-2 lines of therapy and 1-2 versus ≥3 lines of therapy were not significant (P = 0.2349 and P = 0.2375, respectively). The 36-month OS rate was 88%, 83%, and 75% for patients with 0, 1-2, or ≥3 prior therapies, respectively.
| Patients
The ORR was 92% (complete response 
| Concomitant hematologic support measures
Patients received hematologic support, including growth factors, transfusions, and intravenous immunoglobulin (IVIG) (Supporting Information Table 3 ). Rates of neutrophil growth factor use were 10% in the TN subgroup, 28% in patients with 1-2 prior therapies, and 24% in the ≥3 prior therapies subgroup. Rates of IVIG use were 5% in patients with 0 prior therapies, 24% in the 1-2 prior therapies subgroup, and 51% in the ≥3 prior therapies subgroup. Red blood cell and platelet transfusions were also more frequent among patients treated with ibrutinib in later lines (Supporting Information Table 3 ).
| Safety
The hypertension events also occurred after the first year ( Figure 3B ).
Fatal AEs occurred in 11 (8%) TN patients and 11 (8%) R/R patients over the 37 months of follow-up. Fatal AEs included subdural hematoma (n = 1), infections or infectious complications (n = 7), other neoplasms including Richter's transformation (n = 4), myocardial infarction (n = 2), small intestinal obstruction (n = 1), pulmonary fibrosis (n = 1), and other/not specified (n = 6).
| Treatment exposure and discontinuation
Median duration of ibrutinib treatment was 36 months (range, 1-43), 43 months (range, 1-50), and 39 months (range, 1-50) in patients with 0, 1-2, and ≥3 prior treatments, respectively, and the majority of patients continued on ibrutinib (Supporting Information Table 6 ).
The overall rate of ibrutinib discontinuation was 36%. The main reason for discontinuation was progressive disease (PD) for R/R patients, and was AEs for TN patients (Supporting Information Figure 1 ). Discontinuation due to Richter's transformation was higher in R/R compared to TN patients. Discontinuation due to AEs was similar for TN and R/R patients and decreased for all patients as treatment duration increased (Supporting Information Table 6 ). The most common AEs leading to discontinuation (listed as TN or R/R) were infections (4%/5%); malignant, benign, or unspecified neoplasms (2%/5%); nervous system disorders (3%/1%); cardiac disorders (3%/2%); and blood and lymphatic system disorders (1%/2%). The most common AEs leading to dose reductions (in >2 patients) included neutropenia (n = 5; 2%), atrial fibrillation (n = 4; 1%), and anemia, thrombocytopenia, diarrhea, and arthralgia (n = 3; 1% each). Overall, discontinuation due to PD occurred in 32 of 271 patients (12%), including five TN patients (4%; one patient had Richter's transformation) and 27 R/R patients (20%; six patients had Richter's transformation), and occurred less frequently in patients treated with ibrutinib in earlier lines of therapy (Supporting Information Table 6 ).
| Outcomes following ibrutinib discontinuation
Data from 30 TN and 52 R/R patients were evaluated for outcomes following ibrutinib discontinuation ( Table 1 Table 7 ).
When 52 patients who received ibrutinib after crossover were excluded, median OS was 29.4 months for TN patients, versus 2.5 to 2.7 months for patients with ≥1 prior therapy (Supporting Information Table 7 ).
Data on subsequent therapy following ibrutinib discontinuation were available for nine TN patients and 31 R/R patients (Supporting Information Table 8 the frequency of hypertension was found to be higher with ibrutinib than in the comparator arm in RESONATE-2. 6 Patients in this analysis received ibrutinib for longer durations on average than patients receiving comparator drugs; this may partially explain the higher prevalence of hypertension in the ibrutinib arm.
Discontinuation of ibrutinib due to AEs occurred at a similar rate in the TN patients and R/R subgroups without a specific AE markedly predominant; however, the rate of discontinuations due to AEs among real-world patients in a retrospective analysis was higher. 13 Discontinuation due to PD occurred in 12% of patients, similar to the rate of progression-related ibrutinib discontinuation previously reported (10%-12%). Analyses of ibrutinib-treated CLL patients reported poor survival following discontinuation of ibrutinib. 9, 10 One single-institution study reported poor salvageability of 33 patients treated with regimens including chemoimmunotherapy or ofatumumab following ibrutinib discontinuation. 9 Another study of pooled data from 308 patients treated with ibrutinib in four clinical studies confirmed the poor prognosis of patients after discontinuation of ibrutinib. 10 These analyses also revealed that patients who discontinued because of PD with transformation (Richter's or other) had dismal outcomes with median OS of 2.6 to 3.5 months post-ibrutinib discontinuation. 9, 10 In contrast, median OS ranged from 17.6 months to not reached among patients who discontinued because of PD without transformation. 10 Initial reports from these studies indicated that patients who discontinued because of nonrelapse reasons (including AEs) also had a poor prognosis following ibrutinib discontinuation. 9, 10 However, these reports primarily included very high-risk patients with combinations of del(17p), unmutated IGHV, or complex karyotype, who were extensively pretreated, had relapsed early, and/or had exhausted available treatments, including anti-CD20 therapies, alkylating agents, and purine analogs. 9, 10 In addition, few TN patients were included, and follow-up durations were shorter than in the current study. Subsequently, longer follow-up of one study indicated that better survival outcomes were observed in patients who discontinued because of treatment-related toxicity compared with progressive CLL. 15 Consistent with these updated findings, in the present analysis, patients who discontinued because of AEs had better survival outcomes than those who discontinued because of PD, particularly in later lines of therapy.
The studies described above were conducted before the availability of venetoclax or idelalisib; recent studies have shown more favorable outcomes when these novel agents were used following discontinuation of ibrutinib. [16] [17] [18] [19] A multicenter, retrospective study that evaluated 178 patients following discontinuation of ibrutinib or idelalisib (N = 178) reported an ORR of 50% with an alternative kinase inhibitor, 25% with chemoimmunotherapy, 36% with anti-CD20 monoclonal antibody, and 76% with BCL-2 inhibitor therapy. 17 Of the 16 patients who received idelalisib, the ORR was 28%. 17 Results from a phase 2 study of venetoclax showed an ORR of 70% in a subgroup of 43 patients previously treated with ibrutinib. 19 An analysis of patients receiving frontline ibrutinib showed promising results wherein patients responded to chemoimmunotherapy regimens and chlorambucil after discontinuation of ibrutinib. 20 In the present analysis, many patients who received therapies following ibrutinib discontinuation remained alive, albeit with short follow-up. Factors such as number of prior therapies, presence or absence of del(17p), and availability of subsequent therapies, may contribute to the observed differences in post-ibrutinib salvageability across these various studies.
Currently, few patients have progressed on treatment with singleagent ibrutinib. Evolving data from the RESONATE-2 study suggest responses with chemoimmunotherapy after treatment with ibrutinib in the first-line setting is achievable. 20 This integrated, retrospective analysis of the randomized RESO-NATE and RESONATE-2 studies supports once-daily treatment with single-agent ibrutinib leading to high response rates and favorable survival in patients with CLL/SLL, with the best outcomes experienced in those who receive ibrutinib in earlier lines of therapy.
Further, the analysis suggests that the best outcomes following discontinuation of ibrutinib were observed in patients who received ibrutinib in the first-line or second-/third-line settings. As follow-up matures, results of outcomes with subsequent anticancer regimens will allow for a better understanding of salvageability following ibrutinib discontinuation, particularly for those who have not received standard chemoimmunotherapy.
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